Emergency Department Burden of Gastroparesis in the United States, 2006 to 2013.


Journal

Journal of clinical gastroenterology
ISSN: 1539-2031
Titre abrégé: J Clin Gastroenterol
Pays: United States
ID NLM: 7910017

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 20 12 2017
medline: 24 4 2020
entrez: 20 12 2017
Statut: ppublish

Résumé

Gastroparesis, a chronic gastrointestinal disorder defined by delayed stomach emptying in the absence of obstruction, is often associated with frequent and costly visits to the emergency department (ED). The aim of this study was to analyze trends in gastroparesis-related ED visits from 2006 to 2013. Patients with a primary diagnosis of gastroparesis were identified from the Nationwide Emergency Department Sample (NEDS), the largest publicly available ED all-payer representative database in the United States. ED visits, admission rates, duration of hospitalizations, and charges were compiled. Patients with a secondary diagnosis of diabetes mellitus were analyzed as a subgroup. The number of ED visits for gastroparesis as a primary diagnosis in the United States increased from 15,459 in 2006 to 36,820 in 2013, an increase from 12.9 to 27.3 per 100,000 ED visits. The total charges associated with these ED visits and subsequent admissions increased from $286 million to $592 million. In contrast, admission rates through the ED decreased by 22%, procedure rates decreased by 6.2%, and the mean length of stay was shortened by 0.6 days. ED visits for patients with diabetic gastroparesis increased from 5696 to 14,114, an increase from 4.7 to 10.5 per 100,000 ED visits, with an increase in total associated charges for ED visits and subsequent admissions from $84 million to $182 million. The number of ED visits and associated charges for a primary diagnosis of gastroparesis with or without a secondary diagnosis of diabetes mellitus rose significantly from 2006 to 2013.

Sections du résumé

BACKGROUND AND AIMS
Gastroparesis, a chronic gastrointestinal disorder defined by delayed stomach emptying in the absence of obstruction, is often associated with frequent and costly visits to the emergency department (ED). The aim of this study was to analyze trends in gastroparesis-related ED visits from 2006 to 2013.
MATERIALS AND METHODS
Patients with a primary diagnosis of gastroparesis were identified from the Nationwide Emergency Department Sample (NEDS), the largest publicly available ED all-payer representative database in the United States. ED visits, admission rates, duration of hospitalizations, and charges were compiled. Patients with a secondary diagnosis of diabetes mellitus were analyzed as a subgroup.
RESULTS
The number of ED visits for gastroparesis as a primary diagnosis in the United States increased from 15,459 in 2006 to 36,820 in 2013, an increase from 12.9 to 27.3 per 100,000 ED visits. The total charges associated with these ED visits and subsequent admissions increased from $286 million to $592 million. In contrast, admission rates through the ED decreased by 22%, procedure rates decreased by 6.2%, and the mean length of stay was shortened by 0.6 days. ED visits for patients with diabetic gastroparesis increased from 5696 to 14,114, an increase from 4.7 to 10.5 per 100,000 ED visits, with an increase in total associated charges for ED visits and subsequent admissions from $84 million to $182 million.
CONCLUSIONS
The number of ED visits and associated charges for a primary diagnosis of gastroparesis with or without a secondary diagnosis of diabetes mellitus rose significantly from 2006 to 2013.

Identifiants

pubmed: 29256990
doi: 10.1097/MCG.0000000000000972
pmc: PMC6005709
mid: NIHMS920458
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-113

Subventions

Organisme : NCCIH NIH HHS
ID : R01 AT008573
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007760
Pays : United States

Références

Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38
pubmed: 23147521
Gastroenterol Clin North Am. 2007 Sep;36(3):619-47, ix
pubmed: 17950441
J Clin Gastroenterol. 2018 Jan;52(1):20-24
pubmed: 27775961
Dig Dis Sci. 1998 Nov;43(11):2398-404
pubmed: 9824125
Arch Intern Med. 2000 Oct 9;160(18):2808-16
pubmed: 11025791
Am J Gastroenterol. 1999 Apr;94(4):1029-33
pubmed: 10201478
World J Gastroenterol. 2009 Dec 28;15(48):6052-60
pubmed: 20027677
Dig Dis Sci. 2001 Jan;46(1):24-9
pubmed: 11270790
Gastroenterol Clin North Am. 2015 Mar;44(1):9-19
pubmed: 25667019
Clin Gastroenterol Hepatol. 2010 Aug;8(8):676-81
pubmed: 20472097
Can J Gastroenterol. 2001 Dec;15(12):805-13
pubmed: 11773947
Am J Gastroenterol. 1997 Sep;92(9):1501-4
pubmed: 9317072
J Nucl Med Technol. 2008 Mar;36(1):44-54
pubmed: 18287197
Am J Gastroenterol. 2008 Feb;103(2):313-22
pubmed: 18047541
Neurogastroenterol Motil. 2013 May;25(5):389-98, e294
pubmed: 23360151
Emerg Med Clin North Am. 2016 May;34(2):271-91
pubmed: 27133244
Am J Gastroenterol. 2010 Nov;105(11):2357-67
pubmed: 20588262
Arch Intern Med. 2001 Sep 10;161(16):1989-96
pubmed: 11525701
Gastroenterology. 2009 Apr;136(4):1225-33
pubmed: 19249393
Gastroenterology. 2004 Nov;127(5):1592-622
pubmed: 15521026
J Clin Gastroenterol. 2011 Apr;45(4):317-21
pubmed: 20733513
J Nucl Med. 2007 Apr;48(4):568-72
pubmed: 17401093
J Gastroenterol Hepatol. 2007 Sep;22(9):1423-8
pubmed: 17716347
J Gastroenterol Hepatol. 2011 Aug;26(8):1275-82
pubmed: 21443672

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH